Fulminant hepatic failure associated with propylthiouracil. 2003

Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
Department of Medicine, Hospital Carlos Van Buren, Valparaiso, Chile.

OBJECTIVE To report 2 fatal cases of fulminant hepatic failure associated with propylthiouracil treatment against hyperthyroidism. METHODS Two women, 30 and 32 years old with no previous liver disease, were treated with propylthiouracil against Graves' disease. Both patients developed jaundice after a 4- and 5-month treatment period, respectively. The disease was similar to viral hepatitis, with a progressive course to severe liver dysfunction and death, along with multisystem organ failure despite extensive therapeutic measures. One of the patients was pregnant and subsequently miscarried. Neither patient had a history of alcoholism, drug abuse, blood transfusion, or exposure to hepatitis A, B, or C. Extrahepatic obstruction was ruled out with an abdominal ultrasonogram. Serologic studies and immunologic tests were negative. A submassive necrosis was shown in a postmortem histologic study. CONCLUSIONS Naranjo probability scale criteria applied to both cases confirm the adverse reactions as probable. These cases fit the requirements of drug hepatotoxicity proposed by Hanson and the Council of the International Organization of Medical Sciences. Eight deaths associated to propylthiouracil were found in our review of the medical literature up to December 2000. CONCLUSIONS Despite the widespread use of propylthiouracil, fulminant hepatitis with death is exceptionally rare; these 2 cases could be added to the fatal outcomes published to date.

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D011441 Propylthiouracil A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) 6-Propyl-2-Thiouracil,6 Propyl 2 Thiouracil
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D056486 Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment. Drug-Induced Liver Injury,Liver Injury, Drug-Induced,Acute Liver Injury, Drug-Induced,Chemically-Induced Liver Toxicity,Drug-Induced Acute Liver Injury,Drug-Induced Liver Disease,Hepatitis, Drug-Induced,Hepatitis, Toxic,Liver Injury, Drug-Induced, Acute,Toxic Hepatitis,Acute Liver Injury, Drug Induced,Chemically Induced Liver Toxicity,Chemically-Induced Liver Toxicities,Disease, Drug-Induced Liver,Diseases, Drug-Induced Liver,Drug Induced Acute Liver Injury,Drug Induced Liver Disease,Drug Induced Liver Injury,Drug-Induced Hepatitides,Drug-Induced Hepatitis,Drug-Induced Liver Diseases,Drug-Induced Liver Injuries,Hepatitides, Drug-Induced,Hepatitides, Toxic,Hepatitis, Drug Induced,Injuries, Drug-Induced Liver,Injury, Drug-Induced Liver,Liver Disease, Drug-Induced,Liver Diseases, Drug-Induced,Liver Injuries, Drug-Induced,Liver Injury, Drug Induced,Liver Toxicities, Chemically-Induced,Liver Toxicity, Chemically-Induced,Toxic Hepatitides,Toxicities, Chemically-Induced Liver,Toxicity, Chemically-Induced Liver
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
May 2002, Digestive diseases and sciences,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
February 1996, The American journal of gastroenterology,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
November 1997, Urology,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
December 1977, The American journal of gastroenterology,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
February 1997, Urology,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
December 2005, Journal of clinical apheresis,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
January 1989, Clinical transplants,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
December 1997, Urology,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
February 2002, The American journal of gastroenterology,
Jorge K Ruiz, and Giorgio V Rossi, and Humberto A Vallejos, and Rosemarie W Brenet, and Isabel B Lopez, and Alfonso A Escribano
November 2008, Pharmacoepidemiology and drug safety,
Copied contents to your clipboard!